1. Wang J, Zhao B, Song T, Sun J. Lung cancer combined with diffuseperitoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: Acase report. Medicine (Baltimore). 2021;28;100(21):e25961. doi: 10.1097/MD.0000000000025961. PMID: 34032706; PMCID: PMC8154378
2. Behinaein P, Treffalls J, Hutchings H, Okereke IC. The role of sublobarresection for the surgical treatment of non-small cell lung cancer. CurrOncol. 2023:2;30(7):7019-7030. doi: 10.3390/curroncol30070509. PMID:37504369; PMCID: PMC10378348.
3. Enjo -Barreiro JR, Ruano-Ravina A, Diz-de-Almeida S, et al. Genome-Wide association study of small cell lung cancer. Arch bronconeumol.2023 Jul 15:S0300-2896(23)00223-5. English, Spanish. doi: 10.1016/j.arbres.2023.07.008. Epub ahead of print. PMID: 37500326.
4. Kwee TC, Basu S, Cheng G, Alavi A: FDG PET/CT in carcinoma ofunknown primary. Eur J Nucl Med Mol Imaging 2010;37(3):635-644.
5. Melato M, Manconi R, Falconieri G. Amyloidosis and lung cancer. Amorphological and histochemical study. Morphol Embryol (Bucur).1981;27(2):137-142.
6. Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascularsmooth muscle cells. J Neurochem. 1998;70(1):216-223. doi:10.1046/j.1471-4159.1998.70010216.x
7. Gueutin V, Langlois AL, Shehwaro N, Elharraqui R, Rouvier P,Izzedine H. Nephrotic syndrome associated with lung cancer: a rarecase of malignancy associated with aa amyloidosis. Case Rep Nephrol.2013;2013:831903. doi:10.1155/2013/831903
8. Kimball KG. Amyloidosis in association with neoplastic disease.Report of an unusual case and clinicopathological experience atMemorial Center for Cancer and Allied Diseases during eleven years(1948-1958). Ann Intern Med. 1961;55:958-974. doi:10.7326/0003-4819-55-6-958
9. Turkington TG, Coleman RE. Clinical oncologic positron emissiontomography: an introduction. Semin Roentgenol. 2002;37(2):102-109.doi:10.1016/s0037-198x(02)80029-3
10. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retentionindex in dual-phase (18)F-FDG PET, and hexokinase-II andglucose transporter-1 expression in pancreatic cancer. J Nucl Med.2002;43(2):173-180.
11. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K Visualand semiquantitative analyses for F-18 FDG PET scanning in pulmonarynodules 1 cm to 3 cm in size Ann Thorac Surg 2005;79:984-9.
12. Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP.Utility of 18F-FDG PET(/CT) in patients with systemic and localizedamyloidosis. Eur J Nucl Med Mol Imaging. 2013;40(7):1095-1101.doi:10.1007/s00259-013-2375-1